Corporate Finance Adviser to

Corporate Finance Adviser to
on its initial fundraising of $8m

Corporate Finance Adviser to Fastnet Oil & Gas plc

Corporate Finance Adviser to  Fastnet Oil & Gas plc
on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Adviser to

Corporate Finance Adviser to
on its £10m Equity Placing in November 2013

Corporate Finance Adviser to

Corporate Finance Adviser to
on its £10m IPO on the AIM market of the London Stock Exchange

Trade Sale Advisor to Major Shareholder of

Trade Sale Advisor to Major Shareholder of
on its sale to RSA for €65m

Trade Sale Adviser to

Trade Sale Adviser to
  on its sale to Affinion International for €20m+

Trade Sale Adviser to

Trade Sale Adviser to
on its sale to Exponent Private Equity for €170m

Trade Sale Adviser to

Trade Sale Adviser to
on its sale to NASDAQ quoted Verint Systems for $20m+

Trade Sale Adviser to EMAP Plc

Trade Sale Adviser to EMAP Plc
on the Sale of its Irish Radio Assets for €200m

natural-resources-banner

Raglan Pharmaceutical & Life Science Projects

fasnet-logo-reflectRaglan Capital is involved in a number of pharmaceutical and life science ventures including Amryt Pharma. Amryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Amryt’s earlier stage products are focussed on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is high unmet medical needs. These include acromegaly and Cushing's disease.

Amryt Pharma is listed on AIM and ESM. Further details can be found on www.amrytpharma.com